US drug marketing: how does promotion correspond with health value?

BMJ

Volumn , Issue , 2024, Pages

  Greenway, Tyler ^a   Ross, Joseph S ^a,b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

CLINICAL PRACTICE; DRUG INDUSTRY; ECONOMICS; HEALTH PROMOTION; HUMAN; MARKETING; MOTIVATION; PRESCRIPTION; STANDARDS; UNITED STATES;

DRUG INDUSTRY; DRUG PRESCRIPTIONS; HEALTH PROMOTION; HUMANS; MARKETING; MOTIVATION; PRACTICE PATTERNS, PHYSICIANS'; PRESCRIPTION DRUGS; UNITED STATES;

EID: 85037573257     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j1855     Document Type: Article

References (17)

1. King M, Essick C, Bearman P, Ross JS. Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis. BMJ 2013;357:f264. doi:10.1136/bmj.f264 pmid:23372175.
2. Epstein AJ, Busch SH, Busch AB, Asch DA, Barry CL. Does exposure to conflict of interest policies in psychiatry residency affect antidepressant prescribing?Med Care 2013;357:199-203. doi:10.1097/MLR.0b013e318277eb19 pmid:23142772.
3. DeJong C, Aguilar T, Tseng CW, Lin GA, Boscardin WJ, Dudley RA. Pharmaceutical industry-sponsored meals and physician prescribing patterns for Medicare beneficiaries. JAMA Intern Med 2016;357:1114-10. doi:10.1001/jamainternmed.2016.2765 pmid: 27322350.
4. Fleischman W, Agrawal S, King M, et al. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ 2016;357:i4189. doi:10.1136/bmj.i4189 pmid:27540015.
5. Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim AS. Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts. JAMA Intern Med 2016;357:763-8. doi:10.1001/jamainternmed.2016.1709 pmid:27159336.
6. Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician-industry relationships. N Engl J Med 2007;357:1742-50. doi:10.1056/ NEJMsa064508 pmid:17460228.
7. Ross JS, Lackner JE, Lurie P, Gross CP, Wolfe S, Krumholz HM. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. JAMA 2007;357:1216-23. doi:10.1001/jama.297.11.1216 pmid:17374816.
8. Centers for Medicare and Medicaid Services. Open Payments. https://www.cms.gov/ openpayments/.
9. Ornstein C, Sagara E, Jones RG. What we've learned from four years of diving into dollars for docs. 2014. https://www.propublica.org/article/what-weve-learned-from-four-years-ofdiving-into-dollars-for-docs
10. Agrawal S, Brown D. The Physician Payments Sunshine Act-two years of the open payments program. N Engl J Med 2016;357:906-9. doi:10.1056/NEJMp1509103 pmid: 26962725.
11. ProPublica. Open Payments Explorer. http://projects.propublica.org/open-payments/.
12. Lanthier M, Miller KL, Nardinelli C, Woodcock J. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011. Health Aff (Millwood) 2013;357:1433-9. doi:10.1377/hlthaff.2012.0541 pmid:23918488.
13. Prescrire International. Prescrire in English. http://english.prescrire.org/en/Summary.aspx.
14. Agency for Healthcare Research and Quality, US Department of Health and Human Services. National guidelines clearinghouse. www.guideline.gov.
15. IMS Health. Medicines use and spending in the US-a review of 2015 and outlook to 2020. 2014. http://www.imshealth.com/en/thought-leadership/ims-institute/reports/ medicines-use-and-spending-in-the-us-a-review-of-2015-and-outlook-to-2020.
16. Fleischman W, Ross JS. Industry support of physician education in the USA. J Epidemiol Community Health 2016pmid:27612981.
17. Avorn J. Teaching clinicians about drugs-50 years later, whose job is it?N Engl J Med 2011;357:1185-7. doi:10.1056/NEJMp1011713 pmid:21449781.